| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/24/2002 | WO2001019855A3 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001012654A3 Orally active peptides that prevent cell damage and death |
| 01/24/2002 | WO2001008708A3 Enhanced delivery via serpin enzyme complex receptor ligands |
| 01/24/2002 | WO2001006987A3 Transnasal anticonvulsive compositions and modulated process |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000071574A3 Antigenic neisserial peptides |
| 01/24/2002 | WO2000071107A8 New pharmaceutical combinations for nos inhibitors |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010337 Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
| 01/24/2002 | US20020010328 Genetic engineering |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010212 Assay for D-serine transport antagonist and use for treating psychosis |
| 01/24/2002 | US20020010203 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| 01/24/2002 | US20020010201 Method for treating restless leg syndrome using pramipexole and clonidine |
| 01/24/2002 | US20020010198 Treatment of eating disorders, obesity, irritable bowel syndrome, obsessive-compulsive disorders, platelet adhesion, male and female sexual function disorders, restless leg syndrome, osteoarthritis |
| 01/24/2002 | US20020010195 Mitochondria protecting agents for treating mitochondria associated diseases |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010178 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect |
| 01/24/2002 | US20020010174 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 01/24/2002 | US20020010172 Lactams as inhibitors of A-beta protein production |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010168 Boswellic acid, salt or derivatives for preventing and/or combatting diseases caused by increased leucocytic elastase or plasmin activity in human or veterinary medincine, usedfor pulmonary emphysema, acute respiratory distress etc. |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020010138 Treatment of neuromuscular disorders and conditions with different botulinum |
| 01/24/2002 | US20020009752 Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |
| 01/24/2002 | US20020009743 That proliferate in an in vitro culture, obtained by differentiating primate pluripotent stem (pPS) cells, where certain proportion of cells are committed to form neuronal cells, glial cells, or both; screening compounds |
| 01/24/2002 | US20020009740 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 01/24/2002 | US20020009494 Spray drying |
| 01/24/2002 | US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/24/2002 | US20020009478 Aqueous liquid containing colloidal particles |
| 01/24/2002 | US20020009461 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 01/24/2002 | US20020009439 Central nervous system disorders therapy; genetic engineered culture; Alzheimer's disease |
| 01/24/2002 | DE10033459A1 New aminomethyl-substituted bicyclic compounds, useful for treating urinary incontinence, pruritis, tinnitus, diarrhea or especially pain |
| 01/24/2002 | CA2419626A1 Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders |
| 01/24/2002 | CA2416986A1 Crf2 ligands in combination therapy |
| 01/24/2002 | CA2416248A1 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | CA2416245A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | CA2416015A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | CA2415938A1 Alpha-msh related compounds and methods of use |
| 01/24/2002 | CA2415935A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | CA2415906A1 Compositions containing diacyltartaric salts of (e)-metanicotine |
| 01/24/2002 | CA2415901A1 Pharmaceutical compositions and methods for use |
| 01/24/2002 | CA2415697A1 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 01/24/2002 | CA2415673A1 Tetrazole derivatives |
| 01/24/2002 | CA2415665A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | CA2415557A1 Compounds for the treatment of sexual dysfunction |
| 01/24/2002 | CA2415392A1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | CA2414674A1 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 01/24/2002 | CA2410898A1 Substrates and assays for .beta.-secretase activity |
| 01/24/2002 | CA2391791A1 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence |
| 01/24/2002 | CA2384041A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/23/2002 | EP1174504A1 Apoptosis-associated gene |
| 01/23/2002 | EP1174137A1 Patches containing buprenorphine hydrochloride |
| 01/23/2002 | EP1174131A1 Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173764A1 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12 |
| 01/23/2002 | EP1173571A2 Human ion channel proteins |
| 01/23/2002 | EP1173569A1 Synthetic signalling molecules |
| 01/23/2002 | EP1173568A2 Laminin 2 and methods for its use |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173561A2 Non-invasive method for detecting target rna |
| 01/23/2002 | EP1173548A2 Materials and methods relating to neuronal development |
| 01/23/2002 | EP1173480A2 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 01/23/2002 | EP1173479A1 49 human secreted proteins |
| 01/23/2002 | EP1173478A1 49 human secreted proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173465A1 Novel human voltage-gated potassium channel |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173440A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
| 01/23/2002 | EP1173438A1 Substituted imidazoles, their preparation and use |
| 01/23/2002 | EP1173432A1 Piperidine-indole compounds having 5-ht6 affinity |
| 01/23/2002 | EP1173431A2 Method for the preparation of citalopram |
| 01/23/2002 | EP1173424A1 Pyrimidine compounds |
| 01/23/2002 | EP1173254A2 Novel treatment of neurotraumatic conditions with a raf inhibitor |
| 01/23/2002 | EP1173252A1 Products and methods for brachytherapy |
| 01/23/2002 | EP1173215A1 Over-coated chewing gum formulations |
| 01/23/2002 | EP1173201A1 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 01/23/2002 | EP1173200A1 Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins |
| 01/23/2002 | EP1173196A1 New use of a substance in pns |
| 01/23/2002 | EP1173179A2 Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 01/23/2002 | EP1173175A1 A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
| 01/23/2002 | EP1173169A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 01/23/2002 | EP1173168A2 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 01/23/2002 | EP1173164A2 Estrogen receptor-beta ligands |
| 01/23/2002 | EP1173160A1 (e)-styryl sulfone anticancer agents |
| 01/23/2002 | EP1173155A1 Gum pad for delivery of medication to mucosal tissues |
| 01/23/2002 | EP1056856B1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 01/23/2002 | EP1025100B1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 01/23/2002 | EP0854711B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 01/23/2002 | EP0797590B1 Neurotrophic peptides of activity dependent neurotrophic factor |
| 01/23/2002 | EP0745093B1 New oligopeptides with affinity to opioid receptors |
| 01/23/2002 | EP0711292B1 Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| 01/23/2002 | EP0696205B1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 01/23/2002 | EP0687265B1 Heterocyclic compounds and their preparation and use |
| 01/23/2002 | CN1332803A Streptococcus antigens |
| 01/23/2002 | CN1332744A Tricyclic delta 3-piperidines as alpha 2-antagonists |
| 01/23/2002 | CN1332741A Pyrazolopyridine derivatives as selective COX-2 inhibitors |
| 01/23/2002 | CN1332740A 5HT antagonists for antidepressant therapy |